SCHEMBL31358853

SCHEMBL31358853

O=C1C(=Cc2ccc(-c3ccc([N+](=O)[O-])cc3Cl)o2)Cc2ccccc21

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.60
ALDH1A1 P00352 4/20 0.60
POLB P06746 4/20 0.60
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HPGD P15428 3/20 0.52
GSK3A P49840 2/20 0.49
GSK3B P49841 2/20 0.49
KDM4E B2RXH2 2/20 0.46
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
RAB9A P51151 2/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
PTGS2 P35354 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358779 0.92 GSK3A (0.59) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358673 0.88 MAPT (0.58) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358879 0.86 ALDH1A1 (0.57) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358861 0.84 MAPT (0.51) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358799 0.84 KMT2A (0.66) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358690 0.83 MAPT (0.58) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358867 0.82 MAPT (0.58) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358804 0.82 MAPT (0.53) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL31358790 0.81 ALDH1A1 (0.52) MAPTALDH1A1POLBHPGDGSK3A
SCHEMBL31358743 0.80 MAPT (0.57) MAPTALDH1A1POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 MAPT 4688/4885ALDH1A1 3926/4885POLB 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.